# Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children

> **NCT00364793** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 56 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)

## Key facts

- **NCT ID:** NCT00364793
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2011-12
- **Final completion:** 2013-07
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2014-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00364793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00364793, "Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00364793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*